The subcutaneous vaccination of HER2-expressing cancer patients in a phase I clinical study showed HER2-specific CD8+ and/or CD4+ T-cell immune responses, along with the adverse effect of grade 1 transient skin reaction at the site of vaccination. Here, ERBB2 is linked to skin reaction.